Sagar Munjal

1.7k total citations · 1 hit paper
39 papers, 1.2k citations indexed

About

Sagar Munjal is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Physiology. According to data from OpenAlex, Sagar Munjal has authored 39 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Psychiatry and Mental health, 16 papers in Pathology and Forensic Medicine and 15 papers in Physiology. Recurrent topics in Sagar Munjal's work include Migraine and Headache Studies (30 papers), Trigeminal Neuralgia and Treatments (15 papers) and Sympathectomy and Hyperhidrosis Treatments (11 papers). Sagar Munjal is often cited by papers focused on Migraine and Headache Studies (30 papers), Trigeminal Neuralgia and Treatments (15 papers) and Sympathectomy and Hyperhidrosis Treatments (11 papers). Sagar Munjal collaborates with scholars based in United States, India and France. Sagar Munjal's co-authors include Richard B. Lipton, Michael L. Reed, Kristina M. Fanning, David W. Dodick, Todd J. Schwedt, Dawn C. Buse, Aftab Alam, Elimor Brand‐Schieber, Preeti Singh and Hans J. Roethig and has published in prestigious journals such as Neurology, Headache The Journal of Head and Face Pain and Cephalalgia.

In The Last Decade

Sagar Munjal

39 papers receiving 1.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study

2020 194 citations Dawn C. Buse, Michael L. Reed et al. The Journal of Headache and Pain profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Sagar Munjal	857	503	381	101	94	39	1.2k
David Millson	619 0.7×	390 0.8×	353 0.9×	46 0.5×	90 1.0×	45	1.1k
Katherine J. Selzler	645 0.8×	401 0.8×	295 0.8×	42 0.4×	34 0.4×	18	795
Jane Saiers	771 0.9×	511 1.0×	412 1.1×	68 0.7×	113 1.2×	21	1.0k
Robert Croop	1.4k 1.6×	858 1.7×	594 1.6×	142 1.4×	206 2.2×	106	2.0k
Lanfranco Pellesi	639 0.7×	390 0.8×	250 0.7×	26 0.3×	59 0.6×	54	825
Tahir Kurtuluş Yoldaş	225 0.3×	75 0.1×	214 0.6×	21 0.2×	70 0.7×	65	1.0k
Stephen O’Quinn	1.4k 1.6×	1.0k 2.0×	803 2.1×	117 1.2×	168 1.8×	28	1.5k
Mark J. Stillman	506 0.6×	246 0.5×	263 0.7×	22 0.2×	95 1.0×	52	1.1k
F Rossi	204 0.2×	79 0.2×	109 0.3×	28 0.3×	75 0.8×	26	616
Cristina Lopez‐Lopez	178 0.2×	106 0.2×	268 0.7×	8 0.1×	49 0.5×	22	891

Countries citing papers authored by Sagar Munjal

Since Specialization

Citations

This map shows the geographic impact of Sagar Munjal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sagar Munjal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sagar Munjal more than expected).

Fields of papers citing papers by Sagar Munjal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sagar Munjal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sagar Munjal. The network helps show where Sagar Munjal may publish in the future.

Co-authorship network of co-authors of Sagar Munjal

This figure shows the co-authorship network connecting the top 25 collaborators of Sagar Munjal. A scholar is included among the top collaborators of Sagar Munjal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sagar Munjal. Sagar Munjal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bhatt, Anant Narayan, Sagar Munjal, Apurva Agarwal, et al.. (2022). 2-deoxy-d-glucose as an adjunct to standard of care in the medical management of COVID-19: a proof-of-concept and dose-ranging randomised phase II clinical trial. BMC Infectious Diseases. 22(1). 669–669. 28 indexed citations

Lipton, Richard B., et al.. (2021). A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Tolerability, and Safety of Celecoxib Oral Solution (ELYXYB) in Acute Treatment of Episodic Migraine with or without Aura. Journal of Pain Research. Volume 14. 2529–2542. 11 indexed citations

Lipton, Richard B., et al.. (2021). Acute Treatment of Migraine with Celecoxib Oral Solution: Results of a Randomized, Placebo-Controlled Clinical Trial. Journal of Pain Research. Volume 14. 549–560. 4 indexed citations

Buse, Dawn C., Michael L. Reed, Kristina M. Fanning, et al.. (2020). Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. The Journal of Headache and Pain. 21(1). 23–23. 194 indexed citations breakdown →

Alam, Aftab, Sagar Munjal, Michael L. Reed, et al.. (2019). Triptan Use and Discontinuation in a Representative Sample of Persons With Migraine: Results From Migraine in America Symptoms and Treatment (MAST) Study (P4.10-019). Neurology. 92(15_supplement). 5 indexed citations

Pavlović, Jelena, Dawn C. Buse, Michael L. Reed, et al.. (2019). Women with migraine vary in time to peak headache pain intensity, functional impairment and pain interference based on menstrual migraine status: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study (S59.004). Neurology. 92(15_supplement). 1 indexed citations

Lipton, Richard B., Sagar Munjal, Elimor Brand‐Schieber, & Alan M. Rapoport. (2019). DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment. CNS Drugs. 33(4). 375–382. 8 indexed citations

Landy, Stephen H., Sagar Munjal, Elimor Brand‐Schieber, & Alan M. Rapoport. (2018). Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study. The Journal of Headache and Pain. 19(1). 69–69. 15 indexed citations

Landy, Stephen H., Sagar Munjal, Elimor Brand‐Schieber, & Alan M. Rapoport. (2018). Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study. The Journal of Headache and Pain. 19(1). 70–70. 7 indexed citations

10.

Schwedt, Todd J., Aftab Alam, Michael L. Reed, et al.. (2018). Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. The Journal of Headache and Pain. 19(1). 38–38. 100 indexed citations

11.

Gautam, Anirudh, et al.. (2017). Pharmacokinetic Characterization and Dose Selection of a Novel Sumatriptan Nasal Spray Formulation, DFN‐02. The Journal of Clinical Pharmacology. 57(11). 1472–1478. 2 indexed citations

12.

Munjal, Sagar, et al.. (2017). Efficacy and safety of DFN-15, an oral liquid formulation of celecoxib, in adults with migraine: a multicenter, randomized, placebo-controlled, double-blind, crossover study. Neuropsychiatric Disease and Treatment. Volume 13. 2797–2802. 6 indexed citations

13.

Cady, Roger, et al.. (2017). Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine. The Journal of Headache and Pain. 18(1). 17–17. 26 indexed citations

14.

Gautam, Anirudh, et al.. (2017). Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers. Clinical Drug Investigation. 37(10). 937–946. 16 indexed citations

15.

Andre, Anthony D., Elimor Brand‐Schieber, Margarita Ramírez, Sagar Munjal, & Rajesh Kumar. (2017). Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs. Patient Preference and Adherence. Volume 11. 121–129. 12 indexed citations

16.

Munjal, Sagar, et al.. (2017). A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine. The Journal of Headache and Pain. 18(1). 31–31. 21 indexed citations

17.

Andre, Anthony D., et al.. (2016). Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients. Medical Devices Evidence and Research. 9. 131–131. 10 indexed citations

18.

Unverdorben, Martin, et al.. (2010). Acute effects of cigarette smoking on pulmonary function. Regulatory Toxicology and Pharmacology. 57(2-3). 241–246. 28 indexed citations

19.

Roethig, Hans J., Sagar Munjal, Shixia Feng, et al.. (2009). Population estimates for biomarkers of exposure to cigarette smoke in adult U.S. cigarette smokers. Nicotine & Tobacco Research. 11(10). 1216–1225. 86 indexed citations

20.

Mendes, Paul, et al.. (2009). The relationship between smoking machine derived tar yields and biomarkers of exposure in adult cigarette smokers in the US. Regulatory Toxicology and Pharmacology. 55(1). 17–27. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact